Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

Wanwarang Wongcharoen, MD.200 enrolled

Overview

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

200

Conditions

Coronary Artery Bypass Grafting

Interventions

Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)

PlaceboOTHER

Placebo in capsule form, 4 capsules 4 times/day

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Patients undergoing CABG without valve surgery Exclusion Criteria: * emergency cardiac surgery * any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization * patients with cholestatic jaundice (total bilirubin \> 2-fold ULN) * severe liver disease (AST or ALT \> 3-fold ULN)

Locations (1)

Maharaj Nakorn Chiang Mai hospital

Chiang Mai, Thailand

Outcomes

Primary Outcomes

Incidence of postoperative myocardial infarction

Time frame: participants will be followed for the duration of hospital stay, an expected average of 10 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.